GLPwatch
Role of endogenous GLP-1 and its agonists in osteopenia and osteoporosis: but we little know until tried.
Curr Diabetes Rev · 2014
Last updated 2026-05-28A review of studies suggests that GLP-1 and its medications may help improve bone health in people with type 2 diabetes, but most evidence comes from lab or animal research rather than human trials. The exact ways GLP-1 affects bones are still unclear, and more clinical trials are needed to confirm any benefits for bone strength or osteoporosis.
AI summary of the abstract below.
| Journal | Curr Diabetes Rev, 2014 |
|---|---|
| Citations | 5 |
| Relative citation ratio | 0.20 |
| NIH percentile | 13 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
The present brief review looks at the evidence on the role of GLP-1 and its agonists in osteopenia and osteoporosis in type 2 diabetes (T2DM). There is accumulating data to suggest a favourable effect of GLP-1 on bone metabolism. However, most data is from experimental studies, while clinical confirmation is still inadequate. Moreover, little is known on the precise mechanisms underlying these effects. Therefore, we need randomised clinical trials in T2DM patients to learn more on the action of GLP-1 on bone metabolism and its potential clinical implications.
Verbatim abstract via PubMed 24527734 ↗